KR950007862A - Antithrombotic agent and preparation method thereof - Google Patents

Antithrombotic agent and preparation method thereof Download PDF

Info

Publication number
KR950007862A
KR950007862A KR1019930018376A KR930018376A KR950007862A KR 950007862 A KR950007862 A KR 950007862A KR 1019930018376 A KR1019930018376 A KR 1019930018376A KR 930018376 A KR930018376 A KR 930018376A KR 950007862 A KR950007862 A KR 950007862A
Authority
KR
South Korea
Prior art keywords
agent
antithrombotic
green tea
antithrombotic agent
agent according
Prior art date
Application number
KR1019930018376A
Other languages
Korean (ko)
Other versions
KR970011555B1 (en
Inventor
윤여표
문동철
이용문
이세창
박종범
Original Assignee
허계성
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 허계성 filed Critical 허계성
Priority to KR1019930018376A priority Critical patent/KR970011555B1/en
Priority to DE4432549A priority patent/DE4432549A1/en
Priority to JP6218778A priority patent/JPH07258103A/en
Priority to FR9410898A priority patent/FR2709965A1/en
Priority to CN94115295A priority patent/CN1087613C/en
Publication of KR950007862A publication Critical patent/KR950007862A/en
Application granted granted Critical
Publication of KR970011555B1 publication Critical patent/KR970011555B1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/82—Theaceae (Tea family), e.g. camellia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
    • A61K2236/30—Extraction of the material
    • A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Botany (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pyrane Compounds (AREA)

Abstract

본 발명은 항헐전제, 혈전형성억제제 또는 혈전형성원인억제제에 관한 것이다.The present invention relates to anti-thrombotic agents, thrombogenic inhibitors or inhibitors of thrombogenic agents.

더욱 상세하게 설명하자면, 뛰어난 혈전형성원인을 차단하는 작용과 안정성을 가지며, 신규이며, 또한 진보성이 있는 개량 개법에 의하여, 약리적으로 허용되는 녹차엽액기스의 분말을 유효성분으로 하여 이루어진 항혈전재, 혈전형성억제제 또는 혈전형성원인억제제에 관한 것이다.In more detail, the antithrombotic material and thrombus formed by using the powder of green tea leaf extract pharmacologically acceptable as an active ingredient, which has a function and stability to block the cause of excellent thrombus formation, and a novel and progressive improvement method. It relates to an inhibitor of formation or an inhibitor of thrombogenic factors.

본 발명은 녹차의 추출물을 유효성분으로 함유하고 통상의 부형제, 희석제, 항산화제, 및 기타 약학적 제제의 제조에 통상으로 사용되는 보조제를 함유하는 항혈전제 및 그의 제조방법을 제공한다.The present invention provides an antithrombotic agent containing a extract of green tea as an active ingredient and an adjuvant commonly used in the preparation of conventional excipients, diluents, antioxidants, and other pharmaceutical preparations, and a method for producing the same.

Description

항혈전제 및 그 제조방법Antithrombotic agent and preparation method thereof

본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음Since this is an open matter, no full text was included.

Claims (10)

녹차추출물을 유효성분으로 함유하고 통상의 약제학적으로 사용되는 보조제와 통상의 방법으로 통상의 제형으로 제제화하여 제조된 항혈전제.An antithrombotic agent containing green tea extract as an active ingredient and formulated in a conventional formulation by a conventional pharmaceutical adjuvant and a conventional method. 제1항에서 통상의 제제가 산제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a powder. 제1항에서 통상의 제제가 정제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a tablet. 제1항에서 통상의 제제가 캅셀제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a capsule agent. 제1항에서 통상의 제제가 액제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a liquid. 제1항에서 통상의 제제가 연질캅셀제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a soft capsule agent. 제l항에서 통상의 제제가 주사제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is an injection. 제1항에서 통상의 제제가 과립제인 항혈전제.The antithrombotic agent according to claim 1, wherein the conventional agent is a granule. 녹차추출물을 유효성분으로 하고 여기에 통상의 약제학적으로 사용되는 보조제와 통상의 방법으로 통상의 제형으로 제제화하여 항혈전제를 제조하는 방법.A method for preparing an antithrombotic agent by using green tea extract as an active ingredient and formulating it in a conventional formulation by a conventional pharmaceutical adjuvant and a conventional method. 녹차염건조물, 덕음차 또는 시판녹차를 물 또는 물과 저급알콜의 혼합물로 열수 추출하고 불용물질을 제거한 용액을 농축한 후 다시 물에 용해시키고 유기용제로 추출하여 비극성화합물질을 제거한 다음 수층을 농축하고 칼럼으로 분리한 액을 농축시켜서 녹차추출물을 제조하는 방법.Green tea salt dried, Deokeum tea or commercial green tea was extracted with hot water with water or a mixture of water and lower alcohol, concentrated solution was removed from insoluble matters, dissolved in water and extracted with organic solvent to remove nonpolar compound And concentrating the liquid separated in a column to produce green tea extract. ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.※ Note: The disclosure is based on the initial application.
KR1019930018376A 1993-09-13 1993-09-13 Green tea extract im antithrombotic agent and a process for preparing the same KR970011555B1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1019930018376A KR970011555B1 (en) 1993-09-13 1993-09-13 Green tea extract im antithrombotic agent and a process for preparing the same
DE4432549A DE4432549A1 (en) 1993-09-13 1994-09-13 Pharmaceutical products with antithrombotic activity and process for the production thereof
JP6218778A JPH07258103A (en) 1993-09-13 1994-09-13 Antithrombosis agent and its preparation
FR9410898A FR2709965A1 (en) 1993-09-13 1994-09-13 Pharmaceutical compositions having antithrombotic activity and process for their preparation
CN94115295A CN1087613C (en) 1993-09-13 1994-09-13 Pharmaceutical preparations having antithrombotic activity and process for preparing same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1019930018376A KR970011555B1 (en) 1993-09-13 1993-09-13 Green tea extract im antithrombotic agent and a process for preparing the same

Publications (2)

Publication Number Publication Date
KR950007862A true KR950007862A (en) 1995-04-15
KR970011555B1 KR970011555B1 (en) 1997-07-12

Family

ID=19363442

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930018376A KR970011555B1 (en) 1993-09-13 1993-09-13 Green tea extract im antithrombotic agent and a process for preparing the same

Country Status (5)

Country Link
JP (1) JPH07258103A (en)
KR (1) KR970011555B1 (en)
CN (1) CN1087613C (en)
DE (1) DE4432549A1 (en)
FR (1) FR2709965A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005301A (en) * 1995-07-28 1997-02-19 아키히코 키무라 Blood pressure inhibitors with superoxide dismutase action

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19810120C1 (en) * 1998-03-09 1999-05-27 Goldwell Gmbh Use of hair treatment composition
FI20000004A0 (en) * 2000-01-03 2000-01-03 Slk Foundation Flavonoidilääke ...
JP2001245591A (en) * 2000-03-07 2001-09-11 Saitama Prefecture Granule of green tea essence with reduced amount of caffeine
WO2005027896A1 (en) * 2003-09-19 2005-03-31 Kissei Pharmaceutical Co., Ltd. Concurrent drugs
JP2005162685A (en) * 2003-12-04 2005-06-23 Taiyo Kagaku Co Ltd Antithrombotic composition
JP2005179251A (en) * 2003-12-19 2005-07-07 Taiyo Kagaku Co Ltd Composition for inhibiting platelet aggregation
JP4702824B2 (en) * 2004-07-22 2011-06-15 三井農林株式会社 Tea polyphenol composition and method for producing the same
EP1928268A1 (en) * 2005-09-30 2008-06-11 DSMIP Assets B.V. Novel compositions containing polyphenols
CH701576B1 (en) * 2007-04-20 2011-02-15 Andreas Bockelmann Drug combination for the prevention of occlusive vascular disease and cancer.
KR100918776B1 (en) * 2009-04-20 2009-09-24 계명대학교 산학협력단 Composition for controlling the increase of blood glucose using polyethylene glycol and gallated catechin
WO2014118997A1 (en) * 2013-01-30 2014-08-07 宏輝システムズ株式会社 Novel polyhydric alcohol base soft capsule preparation
CN116370434B (en) * 2023-02-24 2024-06-18 中南大学 Nanoparticle for targeted treatment of thrombotic diseases and preparation method and application thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02184626A (en) * 1989-01-10 1990-07-19 Itouen:Kk Blood platelet coagulation inhibiting agent

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR970005301A (en) * 1995-07-28 1997-02-19 아키히코 키무라 Blood pressure inhibitors with superoxide dismutase action

Also Published As

Publication number Publication date
JPH07258103A (en) 1995-10-09
FR2709965A1 (en) 1995-03-24
CN1087613C (en) 2002-07-17
CN1107355A (en) 1995-08-30
KR970011555B1 (en) 1997-07-12
DE4432549A1 (en) 1995-03-16

Similar Documents

Publication Publication Date Title
KR950007862A (en) Antithrombotic agent and preparation method thereof
DK8885D0 (en) N-HETEROCYCLYL-4-PIPERIDINAMINE DERIVATIVES AND PROCEDURES FOR PREPARING THEREOF
DK92781A (en) PROCEDURE FOR THE PREPARATION OF INDANDER DERIVATIVES OR ACID ADDITION SALTS THEREOF
CA2320233A1 (en) Farnesyl transferase inhibitors having a piperidine structure and process for preparation thereof
IL102814A0 (en) Pyrazine derivatives,their preparation and pharmaceutical compositions comprising them
CA2072283A1 (en) Process for the preparation of diacetylrhein
HUP9602868A2 (en) 1,7,7-trimethyl-bicyclo[2.2.1]heptane derivative, pharmaceutical compositions containing the same and process for their preparation
JPS6479175A (en) Thiophene derivative
DK163182C (en) DIALKYLAMINOALCOXYBENZYLAL ALCOHOL DERIVATIVES AND PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS AND QUATERNARY AMMONIUM SALTS THEREOF, PROCEDURES FOR PREPARING THEM, PHARMACEUTICAL PREPARATION PREPARING PREPARATION
FR2799660B1 (en) SUPERCRITICAL FLUID EXTRACTION PROCESS
US4304785A (en) Dilignols and dilignol-type compounds
MX9400165A (en) DERIVATIVES OF TER-BUTYLERGOLINE, PROCESS FOR ITS PRODUCTION AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM.
JPS6431727A (en) Dissolution of argininamide and drug composition containing argininamides
CA2000247A1 (en) 4-methyl 2-(4-phenyl 1-piperazinyl) 5-ethyl thiazol derivatives, process for their preparation and pharmaceutical compounds containing the same
US5212201A (en) Xanthine oxidase inhibitor
SE8405118L (en) 4-CHLORO-FURO- (3,4-C) -PYRIDINE DERIVATIVE PROCEDURE FOR PREPARING THEM AND THERAPEUTIC COMPOSITIONS CONTAINING THEM
US4132782A (en) Method for suppressing herpes simplex virus
US6060498A (en) Composition containing antitumor agent
KR940021524A (en) 1,2,5,6-tetrahydropyridine derivatives, preparation method thereof and use thereof in treatment
JP2860385B2 (en) Bisbenzyl isoquinoline derivative
KR950003297A (en) Separation and Purification of Separantin and Alkaloids Containing It from the Plant of the Plant
FI67694B (en) FRAMEWORK FOR THE FRAMEWORK OF THERAPEUTIC ANALYSIS OF BI-PROLINDERIVAT
JPS57116035A (en) Novel benzylideneaminocarboxylic acid derivative and its preparation
RU1825792C (en) 1-phenyl-4(5)-(2,4-dichlorobenzoylhydroxymethyl)-1,2,3-triazole showing fungicidic effect
KR970070004A (en) Agrocybanin compounds as prolyl endopeptidase inhibitors and methods for their preparation

Legal Events

Date Code Title Description
A201 Request for examination
E902 Notification of reason for refusal
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20121009

Year of fee payment: 16

EXPY Expiration of term